1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66671F6BBD74A196985257490006E003C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/using-disease-management-systems-to-thwart-generic-competitors-a-case-study?opendocument
18
19opendocument
203.85.92.139
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Brand Management and Product Leadership Lifecycle Management

Using Disease Management Systems to Thwart Generic Competitors: A Case Study

DB Image

ID: 4246


Features:

Graphics


Words: 2,110


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Companies seeking to develop strategies and tactics that enhance the post-patent success of products can learn from products that maintained market share in the face of generic competition. Novartis’ Clozaril maintained a large percentage of its market share following its patent loss; this study was aimed at identifying and analyzing critical factors enabling Novartis’ Clozaril to successfully stave off competition from generic products. Best Practices, LLC created this case study through its Business Excellence Board (BEB).

Industries Profiled:
Pharmaceutical


Companies Profiled:
Novartis


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.